Evidence map›Paper›PMID 30008316›Full record

ArticleMolecular cell2018

Targeted Enhancer Activation by a Subunit of the Integrator Complex.

Elisa Barbieri, Marco Trizzino, Sarah Ann Welsh, Tori Alexandra Owens, Bruno Calabretta, Martin Carroll, Kavitha Sarma, Alessandro Gardini

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Unveiling the hemolymphatic miRNome composition of the schistosomiasis vector snailCurrent research in parasitology & vector-borne diseases · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Elisa BarbieriThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Marco TrizzinoThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Sarah Ann WelshThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Tori Alexandra OwensThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Bruno CalabrettaSidney Kimmel Cancer Center, Thomas Jefferson Medical School, Philadelphia, PA, USA.
Martin CarrollDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Kavitha SarmaThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Alessandro GardiniThe Wistar Institute, Gene Expression and Regulation Program, 3601 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: agardini@wistar.org.
The Wistar Institute · USSidney Kimmel Cancer Center · USUniversity of Pennsylvania · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$75.9M
Predoctoral Training at the Chemistry-Biology InterfaceT32GM071339 · NIGMS · WISTAR INSTITUTE · PI MARMORSTEIN, RONEN, SPEICHER, DAVID W. · 2005 to 2019
$3.2M
Epigenetic regulation through the formation and resolution of R loopsDP2NS105576 · NINDS · WISTAR INSTITUTE · PI SARMA, KAVITHA · 2017 to 2017
$2.9M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
NCI NIH HHS P30 CA010815NCI NIH HHS R50 CA221838NIGMS NIH HHS T32 GM071339NINDS NIH HHS DP2 NS105576
6 · The paper itself

Abstract

The control of cell fate is an epigenetic process initiated by transcription factors (TFs) that recognize DNA motifs and recruit activator complexes and transcriptional machineries to chromatin. Lineage specificity is thought to be provided solely by TF-motif pairing, while the recruited activators are passive. Here, we show that INTS13, a subunit of the Integrator complex, operates as monocytic/macrophagic differentiation factor. Integrator is a general activator of transcription at coding genes and is required for eRNA maturation. Here, we show that INTS13 functions as an independent sub-module and targets enhancers through Early Growth Response (EGR1/2) TFs and their co-factor NAB2. INTS13 binds poised monocytic enhancers eliciting chromatin looping and activation. Independent depletion of INTS13, EGR1, or NAB2 impairs monocytic differentiation of cell lines and primary human progenitors. Our data demonstrate that Integrator is not functionally homogeneous and has TF-specific regulatory potential, revealing a new enhancer regulatory axis that controls myeloid differentiation.

Indexed as

Cell DifferentiationEnhancer Elements, GeneticCell LineEarly Growth Response Protein 1Early Growth Response Protein 2HumansMonocytesMyeloid Progenitor CellsRepressor ProteinsEarly Growth Response Protein 1Early Growth Response Protein 2EGR1 protein, humanEGR2 protein, humanNAB2 protein, humanRepressor ProteinsEGR1enhancersINTS13myelopoiesisNAB2poised regulatory elements

Identifiers

PMID30008316
PMCPMC6051407
OpenAlexW2811461384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.